All articles by Swagath Bandhakavi
Swagath Bandhakavi
AbbVie seeks FDA approval for TrenibotE to treat glabellar lines
AbbVie is positioning TrenibotE, a serotype E botulinum neurotoxin, as an option for patients exploring aesthetic neurotoxin treatments for the first time
Veraxa Biotech to go public via $1.64bn SPAC deal with Voyager Acquisition
The company is advancing antibody-based therapies using its proprietary BiTAC platform, which enables dual-marker targeting to enhance precision in solid tumour treatment
Roche to expanding US manufacturing footprint with $50bn investment
Roche’s investment is projected to generate more than 12,000 new jobs across the US, including around 6,500 in construction and 1,000 at its upcoming and expanded facilities
Alumis and Acelyrin finalise amended merger agreement with improved terms
The merger aims to create a major late-stage clinical biopharma company dedicated to developing and commercialising innovative therapies for immune-mediated diseases
UK authorises GSK’s Blenrep combinations for treatment-resistant multiple myeloma
The MHRA’s approval of Blenrep was grounded in DREAMM-7 and DREAMM-8 trial data, which showed notable improvements in progression-free survival over standard treatments
GSK’s Penmenvy gets CDC advisory committee support for adolescent vaccination
The panel has recommended including the vaccine in the routine immunisation schedule for adolescents aged 10 and above, subject to final approval and publication of CDC guidelines
MSD signs licensing deal with Cyprumed for oral peptide technology
Cyprumed stands to receive up to $493m from MSD under a licensing agreement covering upfront fees, development progress, regulatory approvals, and sales milestones
INmune Bio collaborates with CGT Catapult to scale manufacturing of cell therapies
The agreement initially aims to scale production of CORDStrom, a cell therapy developed to address the systemic effects of recessive dystrophic epidermolysis bullosa
FDA approves Opdivo and Yervoy combo for first-line HCC treatment
The approval follows results from the Phase 3 CheckMate-9DW trial, which showed a marked survival advantage over current treatments, lenvatinib or sorafenib
PharmaLogic to buy majority stake in Norway-based Agilera from IFE
The planned acquisition supports PharmaLogic’s strategy to build a fully integrated global contract development and manufacturing platform for radiopharmaceutical therapeutics